Core Insights - Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid diagnostic tests, enhancing access to early detection tools for cancer and chronic diseases in Egypt [1][2][10] Product Portfolio - The authorized screening tests include those for colorectal disease, breast self-examination, prostate disease, kidney disease, and H. pylori infection, all designed for point-of-care use [1][3][7] - Tests provide quick results within minutes and do not require laboratory sample processing, making them suitable for diverse clinical and community settings [3][14] Market Need - Colorectal cancer is the 7th most common cancer in Egypt, with an incidence of approximately 5 to 10 cases per 100,000 persons per year, and a concerning trend of late-stage diagnoses [4] - Breast cancer is the most common cancer among women in Egypt, with an age-standardized incidence rate of about 55.4 per 100,000 persons per year, and poorer mortality outcomes due to late-stage diagnosis [5] - Prostate cancer ranks as the fourth most common cancer in Egypt, with increasing incidence rates [6] Health Statistics - Approximately 13% of adults in Egypt are living with chronic kidney disease, which has been among the top five causes of death from 2009 to 2019 [8] - H. pylori infection prevalence in Egypt ranges from 50% to 70%, affecting a significant portion of the population [8] Strategic Impact - The authorization supports national public health efforts to improve early disease detection, enhance health outcomes, and reduce long-term healthcare costs [9][10] - Biomerica's expansion in the Middle East and North Africa (MENA) region is reinforced by this authorization, aligning with global preventive care trends [11]

Zwerling expected to guide the Company to its commercial launchAPOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026. Mr. Zwerling brings more than three deca ...

Core Insights - RetinalGenix Technologies Inc. has partnered with Seer, Inc. to develop a platform for early detection and monitoring of systemic, neurodegenerative, and retinal diseases through advanced imaging and proteomics [1][2][4] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by integrating genetic screening, advanced imaging, and therapeutic development [6] - The company utilizes proprietary technologies such as High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™ to detect physiological changes indicative of various diseases [6] Collaboration Details - The collaboration aims to integrate RetinalGenix's non-invasive retinal imaging with Seer's advanced proteomic profiling to identify disease signatures before clinical symptoms appear [2][3] - The partnership targets critical conditions including Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases [2][3][4] - Seer will conduct research, development, and clinical validation programs to accelerate diagnostic innovation and enable broader deployment of early-detection solutions [3][4] Technological Integration - The integration of ultra-high-resolution retinal imaging with molecular biomarker analysis is intended to create comprehensive biomarker profiles for better disease monitoring and predictive modeling [4][8] - Seer's Proteograph® Product Suite is designed to provide deep, unbiased proteomic insights, overcoming limitations of traditional proteomic technologies [5] Vision and Goals - Both companies share a vision to transform early disease detection and advance personalized precision medicine through the convergence of imaging and proteomics [4][8]

Core Insights - RetinalGenix Technologies Inc. has partnered with Seer, Inc. to develop a platform for early detection and monitoring of systemic, neurodegenerative, and retinal diseases through advanced imaging and proteomics [1][2][4] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by integrating genetic screening, advanced imaging, and therapeutic development [6] - The company utilizes proprietary technologies such as High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™ to detect physiological changes indicative of various diseases [6] Collaboration Details - The collaboration aims to integrate RetinalGenix's non-invasive retinal imaging with Seer's advanced proteomic profiling to identify disease signatures before clinical symptoms appear [2][4] - The partnership targets critical conditions including Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases [2][3][4] - Seer will conduct research, development, and clinical validation programs to accelerate diagnostic innovation and enable broader deployment of early-detection solutions [3][4] Technological Integration - The integration of ultra-high-resolution retinal imaging with molecular biomarker analysis is intended to create comprehensive biomarker profiles for better disease monitoring and predictive modeling [4][8] - Seer's Proteograph Product Suite offers a robust workflow that addresses challenges faced by traditional proteomic technologies, enhancing the potential for biological insights [5] Vision for the Future - Both companies share a vision to transform early disease detection and advance personalized precision medicine through the convergence of imaging and proteomics [4][8]

Company Overview and Strategy - VolitionRx focuses on advancing low-cost, early detection, and treatment monitoring tests in cancer and sepsis[7] - The company's strategy involves licensing its IP to major players, following a low CapEx/low OpEx model similar to its Nu.Q® Vet business[11, 20] - Volition aims to be cash neutral on a full-year basis in 2025, balancing income with expenditure[87] Veterinary Commercial Progress - The Nu.Q® Vet Cancer test is available in over 20 countries[20] - Approximately 120,000 Nu.Q® Vet Cancer tests and test components were sold in 2024[20, 39] - The company has received $23 million in upfront and milestone payments to date, with an additional $5 million milestone payment anticipated in 2025[20] Expansion into Human Diagnostics - Volition is targeting licensing deals in the human sepsis and cancer space in 2025[10] - The company sees a $4 billion opportunity in lung cancer screening, prognostics, and MRD, and a $1 billion+ opportunity in sepsis testing and monitoring[21] - First revenue was recorded for CE-marked product in Q1 2025[85] Financial Performance - Volition recorded approximately $0.25 million in revenue in Q1 2025, a 44% increase over the first quarter of the prior year[87] - Net cash used in operating activities averaged $1.4 million a month, almost 50% lower than the first quarter of 2024[87]